<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39330389</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2309-608X</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>03</Day></PubDate></JournalIssue><Title>Journal of fungi (Basel, Switzerland)</Title><ISOAbbreviation>J Fungi (Basel)</ISOAbbreviation></Journal><ArticleTitle>Review and Current Perspectives on DNA Topoisomerase I and II Enzymes of Fungi as Study Models for the Development of New Antifungal Drugs.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">629</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/jof10090629</ELocationID><Abstract><AbstractText>Fungal infections represent a growing public health problem, mainly stemming from two phenomena. Firstly, certain diseases (e.g., AIDS and COVID-19) have emerged that weaken the immune system, leaving patients susceptible to opportunistic pathogens. Secondly, an increasing number of pathogenic fungi are developing multi-drug resistance. Consequently, there is a need for new antifungal drugs with novel therapeutic targets, such as type I and II DNA topoisomerase enzymes of fungal organisms. This contribution summarizes the available information in the literature on the biology, topology, structural characteristics, and genes of topoisomerase (Topo) I and II enzymes in humans, two other mammals, and 29 fungi (including Basidiomycetes and Ascomycetes). The evidence of these enzymes as alternative targets for antifungal therapy is presented, as is a broad spectrum of Topo I and II inhibitors. Research has revealed the genes responsible for encoding the Topo I and II enzymes of fungal organisms and the amino acid residues and nucleotide residues at the active sites of the enzymes that are involved in the binding mode of topoisomerase inhibitors. Such residues are highly conserved. According to molecular docking studies, antifungal Topo I and II inhibitors have good affinity for the active site of the respective enzymes. The evidence presented in the current review supports the proposal of the suitability of Topo I and II enzymes as molecular targets for new antifungal drugs, which may be used in the future in combined therapies for the treatment of infections caused by fungal organisms.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Andrade-Pavón</LastName><ForeName>Dulce</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-9858-4806</Identifier><AffiliationInfo><Affiliation>Laboratorio de Biología Molecular de Bacterias y Levaduras, Departamento de Microbiología, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Prol. de Carpio y Plan de Ayala. Col. Sto. Tomás, Ciudad de México 11340, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departamento de Fisiología, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Av. Wilfrido Massieu 399, Nueva Industrial Vallejo, Gustavo A. Madero, Ciudad de México 07738, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gómez-García</LastName><ForeName>Omar</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0002-8025-6174</Identifier><AffiliationInfo><Affiliation>Departamento de Química Orgánica, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Prol. de Carpio y Plan de Ayala. Col. Sto. Tomás, Ciudad de México 11340, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villa-Tanaca</LastName><ForeName>Lourdes</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-0055-2991</Identifier><AffiliationInfo><Affiliation>Laboratorio de Biología Molecular de Bacterias y Levaduras, Departamento de Microbiología, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Prol. de Carpio y Plan de Ayala. Col. Sto. Tomás, Ciudad de México 11340, Mexico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Fungi (Basel)</MedlineTA><NlmUniqueID>101671827</NlmUniqueID><ISSNLinking>2309-608X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">DNA topoisomerases</Keyword><Keyword MajorTopicYN="N">Topo I</Keyword><Keyword MajorTopicYN="N">Topo I and II inhibitors</Keyword><Keyword MajorTopicYN="N">Topo II</Keyword><Keyword MajorTopicYN="N">antifungals</Keyword><Keyword MajorTopicYN="N">fungal infections</Keyword><Keyword MajorTopicYN="N">fungus</Keyword><Keyword MajorTopicYN="N">molecular target</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>16</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>16</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>9</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39330389</ArticleId><ArticleId IdType="pmc">PMC11432948</ArticleId><ArticleId IdType="doi">10.3390/jof10090629</ArticleId><ArticleId IdType="pii">jof10090629</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Angarone M. Fungal infections in cancer patients. Cancer Treat. Res. 2014;161:129–155.</Citation><ArticleIdList><ArticleId IdType="pubmed">24706223</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbee D.D., Pierce S.S., Manning J. Opportunistic fungal infections in critical care units. Crit. Care Nurs. Clin. N. Am. 2017;29:67–79. doi: 10.1016/j.cnc.2016.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cnc.2016.09.011</ArticleId><ArticleId IdType="pubmed">28160958</ArticleId></ArticleIdList></Reference><Reference><Citation>Lockhart S.R., Guarner J. Emerging and reemerging fungal infections. Semin. Diagn. Pathol. 2019;36:177–181. doi: 10.1053/j.semdp.2019.04.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.semdp.2019.04.010</ArticleId><ArticleId IdType="pubmed">31010605</ArticleId></ArticleIdList></Reference><Reference><Citation>Suleyman G., Alangaden G.J. Nosocomial fungal infections: Epidemiology, infection control, and prevention. Infect. Dis. Clin. N. Am. 2021;35:1027–1053. doi: 10.1016/j.idc.2021.08.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.idc.2021.08.002</ArticleId><ArticleId IdType="pubmed">34752219</ArticleId></ArticleIdList></Reference><Reference><Citation>Spallone A., Schwartz I.S. Emerging fungal infections. Infect. Dis. Clin. N. Am. 2021;35:261–277. doi: 10.1016/j.idc.2021.03.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.idc.2021.03.014</ArticleId><ArticleId IdType="pubmed">34016278</ArticleId></ArticleIdList></Reference><Reference><Citation>Parsons M.G., Diekema D.J. What Is New in Fungal Infections? Mod. Pathol. 2023;36:100187. doi: 10.1016/j.modpat.2023.100187.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.modpat.2023.100187</ArticleId><ArticleId IdType="pubmed">37059227</ArticleId></ArticleIdList></Reference><Reference><Citation>Mavor A.L., Thewes S., Hube B. Systemic fungal infections caused by Candida species: Epidemiology, infection process and virulence attributes. Curr. Drug Targets. 2005;6:863–874. doi: 10.2174/138945005774912735.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/138945005774912735</ArticleId><ArticleId IdType="pubmed">16375670</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee Y., Puumala E., Robbins N., Cowen L.E. Antifungal drug resistance: Molecular mechanisms in Candida albicans and beyond. Chem. Rev. 2021;121:3390–3411. doi: 10.1021/acs.chemrev.0c00199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.chemrev.0c00199</ArticleId><ArticleId IdType="pmc">PMC8519031</ArticleId><ArticleId IdType="pubmed">32441527</ArticleId></ArticleIdList></Reference><Reference><Citation>Ismadi Y.K.M., Mohamad S., Harun A. Species-specific PCR primers for simultaneous detection of Aspergillus fumigatus, Aspergillus terreus, Candida albicans and Candida glabrata in invasive fungal infections. Malays. J. Pathol. 2023;45:397–403.</Citation><ArticleIdList><ArticleId IdType="pubmed">38155381</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruhnke M. Epidemiology of Candida albicans infections and role of non-Candida-albicans yeasts. Curr. Drug Targets. 2006;7:495–504. doi: 10.2174/138945006776359421.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/138945006776359421</ArticleId><ArticleId IdType="pubmed">16611037</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva L.N., de Mello T.P., de Souza Ramos L., Branquinha M.H., dos Santos A.L. New and promising chemotherapeutics for emerging infections involving drug-resistant non-albicans Candida species. Curr. Top. Med. Chem. 2019;19:2527–2553. doi: 10.2174/1568026619666191025152412.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1568026619666191025152412</ArticleId><ArticleId IdType="pubmed">31654512</ArticleId></ArticleIdList></Reference><Reference><Citation>Gómez-Gaviria M., Ramírez-Sotelo U., Mora-Montes H.M. Non-albicans Candida Species: Immune Response, Evasion Mechanisms, and New Plant-Derived Alternative Therapies. J. Fungi. 2022;9:11. doi: 10.3390/jof9010011.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jof9010011</ArticleId><ArticleId IdType="pmc">PMC9862154</ArticleId><ArticleId IdType="pubmed">36675832</ArticleId></ArticleIdList></Reference><Reference><Citation>Ben-Ami R., Berman J., Novikov A., Bash E., Shachor-Meyouhas Y., Zakin S., Finn T. Multidrug-resistant Candida haemulonii and C. Auris, tel aviv, Israel. Emerg. Infect. Dis. 2017;23:195. doi: 10.3201/eid2302.161486.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2302.161486</ArticleId><ArticleId IdType="pmc">PMC5324804</ArticleId><ArticleId IdType="pubmed">28098529</ArticleId></ArticleIdList></Reference><Reference><Citation>Du H., Bing J., Hu T., Ennis C.L., Nobile C.J., Huang G. Candida auris: Epidemiology, biology, antifungal resistance, and virulence. PLoS Pathog. 2020;16:e1008921. doi: 10.1371/journal.ppat.1008921.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1008921</ArticleId><ArticleId IdType="pmc">PMC7581363</ArticleId><ArticleId IdType="pubmed">33091071</ArticleId></ArticleIdList></Reference><Reference><Citation>Gómez-Gaviria M., Martínez-Álvarez J.A., Chávez-Santiago J.O., Mora-Montes H.M. Candida haemulonii Complex and Candida auris: Biology, Virulence Factors, Immune Response, and Multidrug Resistance. Infect. Drug Resist. 2023;16:1455–1470. doi: 10.2147/IDR.S402754.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IDR.S402754</ArticleId><ArticleId IdType="pmc">PMC10024503</ArticleId><ArticleId IdType="pubmed">36942024</ArticleId></ArticleIdList></Reference><Reference><Citation>Francisco E.C., de Jong A.W., Colombo A.L. Candida haemulonii species complex: A mini-review. Mycopathologia. 2023;188:909–917. doi: 10.1007/s11046-023-00748-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11046-023-00748-8</ArticleId><ArticleId IdType="pubmed">37391535</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz de Alegría-Puig C., Rodríguez-Lozano J., Agüero-Balbin J. Identification and antifungal susceptibility testing of Candida haemulonii complex isolated from clinical samples. Folia Microbiol. 2024;69:165–171. doi: 10.1007/s12223-023-01122-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12223-023-01122-3</ArticleId><ArticleId IdType="pubmed">38148373</ArticleId></ArticleIdList></Reference><Reference><Citation>Góralska K., Blaszkowska J., Dzikowiec M. Neuroinfections caused by fungi. Infection. 2018;46:443–459. doi: 10.1007/s15010-018-1152-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-018-1152-2</ArticleId><ArticleId IdType="pmc">PMC6096918</ArticleId><ArticleId IdType="pubmed">29785613</ArticleId></ArticleIdList></Reference><Reference><Citation>von Lilienfeld-Toal M., Wagener J., Einsele H., Cornely O.A., Kurzai O. Invasive fungal infection: New treatments to meet new challenges. Dtsch. Arztebl. Int. 2019;116:271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6549129</ArticleId><ArticleId IdType="pubmed">31159914</ArticleId></ArticleIdList></Reference><Reference><Citation>Godoy M.C., Dalla Pria H.R.F., Truong M.T., Shroff G.S., Marom E.M. Invasive fungal pneumonia in immunocompromised patients. Radiol. Clin. N. Am. 2022;60:497–506. doi: 10.1016/j.rcl.2022.01.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rcl.2022.01.006</ArticleId><ArticleId IdType="pubmed">35534133</ArticleId></ArticleIdList></Reference><Reference><Citation>Koehler P., Bassetti M., Chakrabarti A., Chen S.C., Colombo A.L., Hoenigl M., Cornely O.A. Defining and managing COVID-19-associated pulmonar aspergilosis: The 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infect. Dis. 2021;21:e149–e162. doi: 10.1016/S1473-3099(20)30847-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30847-1</ArticleId><ArticleId IdType="pmc">PMC7833078</ArticleId><ArticleId IdType="pubmed">33333012</ArticleId></ArticleIdList></Reference><Reference><Citation>Casalini G., Giacomelli A., Ridolfo A., Gervasoni C., Antinori S. Invasive fungal infections complicating COVID-19: A narrative review. J. Fungi. 2021;7:921. doi: 10.3390/jof7110921.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jof7110921</ArticleId><ArticleId IdType="pmc">PMC8620819</ArticleId><ArticleId IdType="pubmed">34829210</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoenigl M., Seidel D., Sprute R., Cunha C., Oliverio M., Goldman G.H., Ibrahim A.S., Carvalho A. COVID-19-associated fungal infections. Nat. Microbiol. 2022;7:1127–1140. doi: 10.1038/s41564-022-01172-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-022-01172-2</ArticleId><ArticleId IdType="pmc">PMC9362108</ArticleId><ArticleId IdType="pubmed">35918423</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinayagamoorthy K., Pentapati K.C., Prakash H. Prevalence, risk factors, treatment and outcome of multidrug resistance Candida auris infections in coronavirus disease (COVID-19) patients: A systematic review. Mycoses. 2022;65:613–624. doi: 10.1111/myc.13447.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/myc.13447</ArticleId><ArticleId IdType="pmc">PMC9115268</ArticleId><ArticleId IdType="pubmed">35441748</ArticleId></ArticleIdList></Reference><Reference><Citation>Kariyawasam R.M., Dingle T.C., Kula B.E., Vandermeer B., Sligl W.I., Schwartz I.S. Defining COVID-19–associated pulmonary aspergillosis: Systematic review and meta-analysis. Clin. Microbiol. Infect. 2022;28:920–927. doi: 10.1016/j.cmi.2022.01.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2022.01.027</ArticleId><ArticleId IdType="pmc">PMC8828380</ArticleId><ArticleId IdType="pubmed">35150878</ArticleId></ArticleIdList></Reference><Reference><Citation>Khojasteh S., Jafarzdeh J., Hosseini S.A., Hagan I., Turki H., Gharehbolagh S.A., Abastabar M., Mahmoudi S. Candida auris and COVID-19: A health threatening combination. Curr. Med. Mycol. 2022;8:44. doi: 10.18502/cmm.8.3.11211.</Citation><ArticleIdList><ArticleId IdType="doi">10.18502/cmm.8.3.11211</ArticleId><ArticleId IdType="pmc">PMC10084486</ArticleId><ArticleId IdType="pubmed">37051551</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai C.S., Lee S.S.J., Chen W.C., Tseng C.H., Lee N.Y., Chen P.L., Li M.C., Syue L.S., Lo C.L., Ko W.C., et al. COVID-19-associated candidiasis and the emerging concern of Candida auris infections. J. Microbiol. Immunol. Infect. 2023;56:672–679. doi: 10.1016/j.jmii.2022.12.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmii.2022.12.002</ArticleId><ArticleId IdType="pmc">PMC9747227</ArticleId><ArticleId IdType="pubmed">36543722</ArticleId></ArticleIdList></Reference><Reference><Citation>Özbek L., Topçu U., Manay M., Esen B.H., Bektas S.N., Aydın S., Özdemir B., Khostelidi S.N., Klimko N., Cornely O., et al. COVID-19-associated mucormycosis: A systematic review and meta-analysis of 958 cases. Clin. Microbiol. Infect. 2023;29:722–731. doi: 10.1016/j.cmi.2023.03.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2023.03.008</ArticleId><ArticleId IdType="pmc">PMC10008766</ArticleId><ArticleId IdType="pubmed">36921716</ArticleId></ArticleIdList></Reference><Reference><Citation>Usuda D., Kato M., Sugawara Y., Shimizu R., Inami T., Tsuge S., Sakurai R., Kawai K., Matsubara S., Tanaka R., et al. Secondary pulmonary infection by Fusarium solani and Aspergillus niger during systemic steroid treatment for COVID-19: A case report. World J. Clin. Cases. 2023;11:6280. doi: 10.12998/wjcc.v11.i26.6280.</Citation><ArticleIdList><ArticleId IdType="doi">10.12998/wjcc.v11.i26.6280</ArticleId><ArticleId IdType="pmc">PMC10507554</ArticleId><ArticleId IdType="pubmed">37731582</ArticleId></ArticleIdList></Reference><Reference><Citation>Perlin D.S., Rautemaa-Richardson R., Alastruey-Izquierdo A. The global problem of antifungal resistance: Prevalence, mechanisms, and management. Lancet Infect. Dis. 2017;17:e383–e392. doi: 10.1016/S1473-3099(17)30316-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(17)30316-X</ArticleId><ArticleId IdType="pubmed">28774698</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma C., Chowdhary A. Molecular bases of antifungal resistance in filamentous fungi. Int. J. Antimicrob. Agents. 2017;50:607–616. doi: 10.1016/j.ijantimicag.2017.06.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2017.06.018</ArticleId><ArticleId IdType="pubmed">28705674</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiederhold N.P. Antifungal resistance: Current trends and future strategies to combat. Infect. Drug Resist. 2017;10:249–259. doi: 10.2147/IDR.S124918.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IDR.S124918</ArticleId><ArticleId IdType="pmc">PMC5587015</ArticleId><ArticleId IdType="pubmed">28919789</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira R., dos Santos Fontenelle R.O., De Brito E.H.S., De Morais S.M. Biofilm of Candida albicans: Formation, regulation and resistance. J. Appl. Microbiol. 2021;131:11–22. doi: 10.1111/jam.14949.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jam.14949</ArticleId><ArticleId IdType="pubmed">33249681</ArticleId></ArticleIdList></Reference><Reference><Citation>Campoy S., Adrio J.L. Antifungals. Biochem. Pharmacol. 2017;133:86–96. doi: 10.1016/j.bcp.2016.11.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2016.11.019</ArticleId><ArticleId IdType="pubmed">27884742</ArticleId></ArticleIdList></Reference><Reference><Citation>Ben-Ami R., Kontoyiannis D.P. Resistance to antifungal drugs. Infect. Dis. Clin. N. Am. 2021;35:279–311. doi: 10.1016/j.idc.2021.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.idc.2021.03.003</ArticleId><ArticleId IdType="pubmed">34016279</ArticleId></ArticleIdList></Reference><Reference><Citation>Gow N.A., Johnson C., Berman J., Coste A.T., Cuomo C.A., Perlin D.S., Bicanic T., Harrison T.S., Wiederhold N., Bromley M., et al. The importance of antimicrobial resistance in medical mycology. Nat. Commun. 2022;13:5352. doi: 10.1038/s41467-022-32249-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-32249-5</ArticleId><ArticleId IdType="pmc">PMC9466305</ArticleId><ArticleId IdType="pubmed">36097014</ArticleId></ArticleIdList></Reference><Reference><Citation>Lupetti A., Danesi R., Campa M., Del Tacca M., Kelly S. Molecular basis of resistance to azole antifungals. Trends Mol. Med. 2022;8:76–81. doi: 10.1016/S1471-4914(02)02280-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1471-4914(02)02280-3</ArticleId><ArticleId IdType="pubmed">11815273</ArticleId></ArticleIdList></Reference><Reference><Citation>Pristov K.E., Ghannoum M.A. Resistance of Candida to azoles and echinocandins worldwide. Clin. Microbiol. Infect. 2019;25:792–798. doi: 10.1016/j.cmi.2019.03.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2019.03.028</ArticleId><ArticleId IdType="pubmed">30965100</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiederhold N.P., Patterson T.F. Emergence of azole resistance in Aspergillus. Semin. Respir. Crit. Care Med. 2015;36:673–680. doi: 10.1055/s-0035-1562894.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0035-1562894</ArticleId><ArticleId IdType="pubmed">26398534</ArticleId></ArticleIdList></Reference><Reference><Citation>Dannaoui E. Antifungal resistance in mucorales. Int. J. Antimicrob. Agents. 2017;50:617–621. doi: 10.1016/j.ijantimicag.2017.08.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2017.08.010</ArticleId><ArticleId IdType="pubmed">28802855</ArticleId></ArticleIdList></Reference><Reference><Citation>García-Rubio R., Cuenca-Estrella M., Mellado E. Triazole resistance in Aspergillus species: An emerging problem. Drugs. 2017;77:599–613. doi: 10.1007/s40265-017-0714-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-017-0714-4</ArticleId><ArticleId IdType="pubmed">28236169</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellsworth M., Ostrosky-Zeichner L. Isavuconazole: Mechanism of action, clinical efficacy, and resistance. J. Fungi. 2020;6:324. doi: 10.3390/jof6040324.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jof6040324</ArticleId><ArticleId IdType="pmc">PMC7712939</ArticleId><ArticleId IdType="pubmed">33260353</ArticleId></ArticleIdList></Reference><Reference><Citation>Pérez-Cantero A., Lopez-Fernandez L., Guarro J., Capilla J. Azole resistance mechanisms in Aspergillus: Update and recent advances. Int. J. Antimicrob. Agents. 2020;55:105807. doi: 10.1016/j.ijantimicag.2019.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2019.09.011</ArticleId><ArticleId IdType="pubmed">31542320</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasula S., Chandrasekar P.H. Azole resistance in Aspergillus species: Promising therapeutic options. Expert. Opin. Pharmacother. 2021;22:2071–2078. doi: 10.1080/14656566.2021.1940134.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14656566.2021.1940134</ArticleId><ArticleId IdType="pubmed">34129410</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamoth F., Lewis R.E., Kontoyiannis D.P. Investigational antifungal agents for invasive mycoses: A clinical perspective. Clin. Infect. Dis. 2022;75:534–544. doi: 10.1093/cid/ciab1070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab1070</ArticleId><ArticleId IdType="pubmed">34986246</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen L.L., Baranowski J., Fostel J., Montgomery D.A., Lartey P.A. DNA topoisomerases from pathogenic fungi: Targets for the discovery of antifungal drugs. Antimicrob. Agents Chemother. 1992;36:2778–2784. doi: 10.1128/AAC.36.12.2778.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.36.12.2778</ArticleId><ArticleId IdType="pmc">PMC245544</ArticleId><ArticleId IdType="pubmed">1336349</ArticleId></ArticleIdList></Reference><Reference><Citation>Tagle-Olmedo T., Andrade-Pavón D., Martínez-Gamboa A., Gómez-García O., García-Sierra F., Hernández-Rodríguez C., Villa-Tanaca L. Inhibitors of DNA topoisomerases I and II applied to Candida dubliniensis reduce growth, viability, the generation of petite mutants and toxicity, while acting synergistically with fluconazole. FEMS Yeast Res. 2021;21:foab023. doi: 10.1093/femsyr/foab023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/femsyr/foab023</ArticleId><ArticleId IdType="pubmed">33837766</ArticleId></ArticleIdList></Reference><Reference><Citation>Kondaka K., Gabriel I. Targeting DNA Topoisomerase II in Antifungal Chemotherapy. Molecules. 2022;27:7768. doi: 10.3390/molecules27227768.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules27227768</ArticleId><ArticleId IdType="pmc">PMC9698242</ArticleId><ArticleId IdType="pubmed">36431868</ArticleId></ArticleIdList></Reference><Reference><Citation>Gellert M. DNA topoisomerases. Annu. Rev. Biochem. 1981;50:879–910. doi: 10.1146/annurev.bi.50.070181.004311.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.bi.50.070181.004311</ArticleId><ArticleId IdType="pubmed">6267993</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J.C. DNA topoisomerases. Annu. Rev. Biochem. 1996;65:635–692. doi: 10.1146/annurev.bi.65.070196.003223.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.bi.65.070196.003223</ArticleId><ArticleId IdType="pubmed">8811192</ArticleId></ArticleIdList></Reference><Reference><Citation>Champoux J.J. DNA topoisomerases: Structure, function, and mechanism. Annu. Rev. Biochem. 2001;70:369–413. doi: 10.1146/annurev.biochem.70.1.369.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.biochem.70.1.369</ArticleId><ArticleId IdType="pubmed">11395412</ArticleId></ArticleIdList></Reference><Reference><Citation>Bush N.G., Evans-Roberts K., Maxwell A. DNA topoisomerases. EcoSal Plus. 2015;6:10–1128. doi: 10.1128/ecosalplus.esp-0010-2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/ecosalplus.esp-0010-2014</ArticleId><ArticleId IdType="pubmed">26435256</ArticleId></ArticleIdList></Reference><Reference><Citation>Joshi R.S., Nikolaou C., Roca J. Structure and chromosomal organization of yeast genes regulated by Topoisomerase II. Int. J. Mol. Sci. 2018;19:134. doi: 10.3390/ijms19010134.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms19010134</ArticleId><ArticleId IdType="pmc">PMC5796083</ArticleId><ArticleId IdType="pubmed">29301361</ArticleId></ArticleIdList></Reference><Reference><Citation>Forterre P., Gribaldo S., Gadelle D., Serre M.C. Origin and evolution of DNA topoisomerases. Biochimie. 2007;89:427–446. doi: 10.1016/j.biochi.2006.12.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biochi.2006.12.009</ArticleId><ArticleId IdType="pubmed">17293019</ArticleId></ArticleIdList></Reference><Reference><Citation>Roca J. The mechanisms of DNA topoisomerases. Trends Biochem. Sci. 1995;20:156–160. doi: 10.1016/S0968-0004(00)88993-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0968-0004(00)88993-8</ArticleId><ArticleId IdType="pubmed">7770916</ArticleId></ArticleIdList></Reference><Reference><Citation>Wigley D.B. Structure and mechanism of DNA topoisomerases. Annu. Rev. Biophys. Biomol. Struct. 1995;24:185–208. doi: 10.1146/annurev.bb.24.060195.001153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.bb.24.060195.001153</ArticleId><ArticleId IdType="pubmed">7663114</ArticleId></ArticleIdList></Reference><Reference><Citation>Bugreev D.V., Nevinsky G.A. Structure and mechanism of action of type IA DNA topoisomerases. Biochemistry. 2009;74:1467–1481. doi: 10.1134/S0006297909130045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1134/S0006297909130045</ArticleId><ArticleId IdType="pubmed">20210704</ArticleId></ArticleIdList></Reference><Reference><Citation>Vos S.M., Tretter E.M., Schmidt B.H., Berger J.M. All tangled up: How cells direct, manage and exploit topoisomerase function. Nat. Rev. Mol. Cell Biol. 2011;12:827–841. doi: 10.1038/nrm3228.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm3228</ArticleId><ArticleId IdType="pmc">PMC4351964</ArticleId><ArticleId IdType="pubmed">22108601</ArticleId></ArticleIdList></Reference><Reference><Citation>Ju B.G., Lunyak V.V., Perissi V., Garcia-Bassets I., Rose D.W., Glass C.K., Rosenfeld M.G. A topoisomerase IIβ-mediated dsDNA break required for regulated transcription. Science. 2006;312:1798–1802. doi: 10.1126/science.1127196.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1127196</ArticleId><ArticleId IdType="pubmed">16794079</ArticleId></ArticleIdList></Reference><Reference><Citation>Chikamori K., G Grozav A., Kozuki T., Grabowski D., Ganapathi R., K Ganapathi M. DNA topoisomerase II enzymes as molecular targets for cancer chemotherapy. Curr. Cancer Drug Targets. 2010;10:758–771. doi: 10.2174/156800910793605785.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156800910793605785</ArticleId><ArticleId IdType="pubmed">20578986</ArticleId></ArticleIdList></Reference><Reference><Citation>Madabhushi R. The roles of DNA topoisomerase IIβ in transcription. Int. J. Mol. Sci. 2018;19:1917. doi: 10.3390/ijms19071917.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms19071917</ArticleId><ArticleId IdType="pmc">PMC6073266</ArticleId><ArticleId IdType="pubmed">29966298</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirsch J., Klostermeier D. What makes a type IIA topoisomerase a gyrase or a Topo IV? Nucleic Acids Res. 2021;49:6027–6042. doi: 10.1093/nar/gkab270.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkab270</ArticleId><ArticleId IdType="pmc">PMC8216471</ArticleId><ArticleId IdType="pubmed">33905522</ArticleId></ArticleIdList></Reference><Reference><Citation>McKie S.J., Desai P.R., Seol Y., Allen A.M., Maxwell A., Neuman K.C. Topoisomerase VI is a chirally-selective, preferential DNA decatenase. eLife. 2022;11:e67021. doi: 10.7554/eLife.67021.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.67021</ArticleId><ArticleId IdType="pmc">PMC8837201</ArticleId><ArticleId IdType="pubmed">35076393</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunze N., Yang G.C., Dölberg M., Sundarp R., Knippers R., Richter A. Structure of the human type I DNA topoisomerase gene. J. Biol. Chem. 1991;266:9610–9616. doi: 10.1016/S0021-9258(18)92864-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9258(18)92864-4</ArticleId><ArticleId IdType="pubmed">1851751</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin C.A., Marsh K.L. Eukaryotic DNA topoisomerase IIβ. Bioessays. 1998;20:215–226. doi: 10.1002/(SICI)1521-1878(199803)20:3&lt;215::AID-BIES5&gt;3.0.CO;2-Q.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1521-1878(199803)20:3&lt;215::AID-BIES5&gt;3.0.CO;2-Q</ArticleId><ArticleId IdType="pubmed">9631649</ArticleId></ArticleIdList></Reference><Reference><Citation>Deneke J., Burgin A.B., Wilson S.L., Chaconas G. Catalytic residues of the telomere resolvase ResT: A pattern similar to, but distinct from, tyrosine recombinases and type IB topoisomerases. J. Biol. Chem. 2004;279:53699–53706. doi: 10.1074/jbc.M409001200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M409001200</ArticleId><ArticleId IdType="pubmed">15471873</ArticleId></ArticleIdList></Reference><Reference><Citation>Brochier-Armanet C., Gribaldo S., Forterre P. A DNA topoisomerase IB in Thaumarchaeota testifies for the presence of this enzyme in the last common ancestor of Archaea and Eucarya. Biol. Direct. 2008;3:54. doi: 10.1186/1745-6150-3-54.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1745-6150-3-54</ArticleId><ArticleId IdType="pmc">PMC2621148</ArticleId><ArticleId IdType="pubmed">19105819</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang W., Gerhold D., Kmiec E.B., Hauser M., Becker J.M., Koltin Y. The topoisomerase I gene from Candida albicans. Microbiology. 1997;143:377–386. doi: 10.1099/00221287-143-2-377.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/00221287-143-2-377</ArticleId><ArticleId IdType="pubmed">9043115</ArticleId></ArticleIdList></Reference><Reference><Citation>Goto T., Wang J.C. Cloning of yeast TOP1, the gene encoding DNA topoisomerase I, and construction of mutants defective in both DNA topoisomerase I and DNA topoisomerase II. Proc. Natl. Acad. Sci. USA. 1985;82:7178–7182. doi: 10.1073/pnas.82.21.7178.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.82.21.7178</ArticleId><ArticleId IdType="pmc">PMC390812</ArticleId><ArticleId IdType="pubmed">2997777</ArticleId></ArticleIdList></Reference><Reference><Citation>Thrash C., Bankier A.T., Barrell B.G., Sternglanz R. Cloning, characterization, and sequence of the yeast DNA topoisomerase I gene. Proc. Natl. Acad. Sci. USA. 1985;82:4374–4378. doi: 10.1073/pnas.82.13.4374.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.82.13.4374</ArticleId><ArticleId IdType="pmc">PMC390416</ArticleId><ArticleId IdType="pubmed">2989818</ArticleId></ArticleIdList></Reference><Reference><Citation>Uemura T., Morino K., Uzawa S., Shiozaki K., Yanagida M. Cloning and sequencing of Schizosaccharomyces pombe DNA topoisomerase I gene, and effect of gene disruption. Nucleic Acids Res. 1987;15:9727–9739. doi: 10.1093/nar/15.23.9727.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/15.23.9727</ArticleId><ArticleId IdType="pmc">PMC306527</ArticleId><ArticleId IdType="pubmed">2827111</ArticleId></ArticleIdList></Reference><Reference><Citation>Uemura T., Yanagida M. Isolation of type I and II DNA topoisomerase mutants from fission yeast: Single and double mutants show different phenotypes in cell growth and chromatin organization. EMBO J. 1984;3:1737–1744. doi: 10.1002/j.1460-2075.1984.tb02040.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/j.1460-2075.1984.tb02040.x</ArticleId><ArticleId IdType="pmc">PMC557590</ArticleId><ArticleId IdType="pubmed">6090122</ArticleId></ArticleIdList></Reference><Reference><Citation>Christman M.F., Dietrich F.S., Fink G.R. Mitotic recombination in the rDNA of S. cerevisiae is suppressed by the combined action of DNA topoisomerases I and II. Cell. 1988;55:413–425. doi: 10.1016/0092-8674(88)90027-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-8674(88)90027-X</ArticleId><ArticleId IdType="pubmed">2902925</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiorani P., Bjornsti M.A. Mechanisms of DNA Topoisomerase I-Induced Cell Killing in the Yeast: Saccharomyces cerevisiae. Ann. N. Y. Acad. Sci. 2000;922:65–75. doi: 10.1111/j.1749-6632.2000.tb07026.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.2000.tb07026.x</ArticleId><ArticleId IdType="pubmed">11193926</ArticleId></ArticleIdList></Reference><Reference><Citation>Losasso C., Cretaio E., Palle K., Pattarello L., Bjornsti M.A., Benedetti P. Alterations in linker flexibility suppress DNA topoisomerase I mutant-induced cell lethality. J. Biol. Chem. 2007;282:9855–9864. doi: 10.1074/jbc.M608200200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M608200200</ArticleId><ArticleId IdType="pubmed">17276985</ArticleId></ArticleIdList></Reference><Reference><Citation>Heldrich J., Sun X., Vale-Silva L.A., Markowitz T.E., Hochwagen A. Topoisomerases modulate the timing of meiotic DNA breakage and chromosome morphogenesis in Saccharomyces cerevisiae. Genetics. 2020;215:59–73. doi: 10.1534/genetics.120.303060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1534/genetics.120.303060</ArticleId><ArticleId IdType="pmc">PMC7198267</ArticleId><ArticleId IdType="pubmed">32152049</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerhold D., Thiyagarajan M., Kmiec E.B. The topoisomerase I gene from Ustilago maydis: Sequence, disruption and mutant phenotype. Nucleic Acids Res. 1994;22:3773–3778. doi: 10.1093/nar/22.18.3773.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/22.18.3773</ArticleId><ArticleId IdType="pmc">PMC308361</ArticleId><ArticleId IdType="pubmed">7937091</ArticleId></ArticleIdList></Reference><Reference><Citation>Choder M. A general topoisomerase I-dependent transcriptional repression in the stationary phase in yeast. Genes Dev. 1991;5:2315–2326. doi: 10.1101/gad.5.12a.2315.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.5.12a.2315</ArticleId><ArticleId IdType="pubmed">1660829</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Poeta M., Chen S.F., Von Hoff D., Dykstra C.C., Wani M.C., Manikumar G., Perfect J.R. Comparison of in vitro activities of camptothecin and nitidine derivatives against fungal and cancer cells. Antimicrob. Agents Chemother. 1999;43:2862–2868. doi: 10.1128/AAC.43.12.2862.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.43.12.2862</ArticleId><ArticleId IdType="pmc">PMC89577</ArticleId><ArticleId IdType="pubmed">10582872</ArticleId></ArticleIdList></Reference><Reference><Citation>Lynn R.M., Bjornsti M.A., Caron P.R., Wang J.C. Peptide sequencing and site-directed mutagenesis identify tyrosine-727 as the active site tyrosine of Saccharomyces cerevisiae DNA topoisomerase I. Proc. Natl. Acad. Sci. USA. 1989;86:3559–3563. doi: 10.1073/pnas.86.10.3559.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.86.10.3559</ArticleId><ArticleId IdType="pmc">PMC287177</ArticleId><ArticleId IdType="pubmed">2542938</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma A., Mondragón A. DNA topoisomerases. Curr. Opin. Struct. Biol. 1995;5:39–47. doi: 10.1016/0959-440X(95)80007-N.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0959-440X(95)80007-N</ArticleId><ArticleId IdType="pubmed">7773745</ArticleId></ArticleIdList></Reference><Reference><Citation>Reguera R.M., Pérez-Pertejo Y., Redondo C.M., Díaz-González R., Balaña-Fouce R. La ADN topoisomerasa tipo I de protozoos patógenos como Diana terapéutica de fármacos antitumorales. Medicina. 2007;67:747–757.</Citation><ArticleIdList><ArticleId IdType="pubmed">18422072</ArticleId></ArticleIdList></Reference><Reference><Citation>Aravind L., Leipe D.D., Koonin E.V. Toprim—A conserved catalytic domain in type IA and II topoisomerases, DnaG-type primases, OLD family nucleases and RecR proteins. Nucleic Acids Res. 1998;26:4205–4213. doi: 10.1093/nar/26.18.4205.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/26.18.4205</ArticleId><ArticleId IdType="pmc">PMC147817</ArticleId><ArticleId IdType="pubmed">9722641</ArticleId></ArticleIdList></Reference><Reference><Citation>Allemand F., Mathy N., Brechemier-Baey D., Condon C. The 5S rRNA maturase, ribonuclease M5, is a Toprim domain family member. Nucleic Acids Res. 2005;33:4368–4376. doi: 10.1093/nar/gki752.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gki752</ArticleId><ArticleId IdType="pmc">PMC1182330</ArticleId><ArticleId IdType="pubmed">16077031</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu G., Wu J., Liu W., Zhu D., Hu Y., Deng J., Wang D.C. Crystal structure of DNA gyrase B′ domain sheds lights on the mechanism for T-segment navigation. Nucleic Acids Res. 2009;37:5908–5916. doi: 10.1093/nar/gkp586.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkp586</ArticleId><ArticleId IdType="pmc">PMC2761264</ArticleId><ArticleId IdType="pubmed">19596812</ArticleId></ArticleIdList></Reference><Reference><Citation>Berger J.M. Type II DNA topoisomerases. Curr. Opin. Struct. Biol. 1998;8:26–32. doi: 10.1016/S0959-440X(98)80006-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0959-440X(98)80006-7</ArticleId><ArticleId IdType="pubmed">9519293</ArticleId></ArticleIdList></Reference><Reference><Citation>Erdős M., Lányi Á., Balázs G., Casanova J.L., Boisson B., Maródi L. Inherited TOP2B mutation: Possible confirmation of mutational hotspots in the TOPRIM domain. J. Clin. Immunol. 2021;41:817–819. doi: 10.1007/s10875-020-00963-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-020-00963-8</ArticleId><ArticleId IdType="pubmed">33459963</ArticleId></ArticleIdList></Reference><Reference><Citation>Gadelle D., Filie J., Buhler C., Forterre P. Phylogenomics of type II DNA topoisomerases. Bioessays. 2003;25:232–242. doi: 10.1002/bies.10245.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bies.10245</ArticleId><ArticleId IdType="pubmed">12596227</ArticleId></ArticleIdList></Reference><Reference><Citation>Coelho J., Martins C., Ferreira F., Leitao A. African swine fever virus ORF P1192R codes for a functional type II DNA topoisomerase. Virology. 2015;474:82–93. doi: 10.1016/j.virol.2014.10.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2014.10.034</ArticleId><ArticleId IdType="pubmed">25463606</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato M., Ozeki M., Kikuchi A., Kanbe T. Phylogenetic relationship and mode of evolution of yeast DNA topoisomerase II gene in the pathogenic Candida species. Gene. 2001;272:275–281. doi: 10.1016/S0378-1119(01)00526-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0378-1119(01)00526-1</ArticleId><ArticleId IdType="pubmed">11470534</ArticleId></ArticleIdList></Reference><Reference><Citation>Shamsizadeh F., Pchelin I.M., Makimura K., Alshahni M.M., Satoh K., Katiraee F., Rezaei-Matehhkolaei A. DNA topoisomerase 2 gene polymorphism in dermatophytes. Mycoses. 2020;63:694–703. doi: 10.1111/myc.13086.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/myc.13086</ArticleId><ArticleId IdType="pubmed">32277529</ArticleId></ArticleIdList></Reference><Reference><Citation>Fostel J.M., Montgomery D.A., Shen L.L. Characterization of DNA topoisomerase I from Candida albicans as a target for drug discovery. Antimicrob. Agents Chemother. 1992;36:2131–2138. doi: 10.1128/AAC.36.10.2131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.36.10.2131</ArticleId><ArticleId IdType="pmc">PMC245467</ArticleId><ArticleId IdType="pubmed">1332588</ArticleId></ArticleIdList></Reference><Reference><Citation>Fostel J., Montgomery D., Lartey P. Comparison of responses of DNA topoisomerase I from Candida albicans and human cells to four new agents which stimulate topoisomerase-dependent DNA nicking. FEMS Microbiol. Lett. 1996;138:105–111. doi: 10.1111/j.1574-6968.1996.tb08142.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1574-6968.1996.tb08142.x</ArticleId><ArticleId IdType="pubmed">9026436</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Dross R.T., Rao K.V., Eisenberg E., Sanders M.M. Cloning and characterization of the Aspergillus nidulans DNA topoisomerase I gene. Gene. 1997;203:169–174. doi: 10.1016/S0378-1119(97)00508-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0378-1119(97)00508-8</ArticleId><ArticleId IdType="pubmed">9426247</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim K.H., Akashi T., Mizuguchi I., Kikuchi A. Cloning and characterization of the gene encoding Aspergillus nidulans DNA topoisomerase II. Gene. 1999;236:293–301. doi: 10.1016/S0378-1119(99)00268-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0378-1119(99)00268-1</ArticleId><ArticleId IdType="pubmed">10452949</ArticleId></ArticleIdList></Reference><Reference><Citation>Nitiss J.L. Yeast as a genetic model system for studying topoisomerase inhibitors. Adv. Pharmacol. 1994;29:201–226.</Citation><ArticleIdList><ArticleId IdType="pubmed">8996609</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng H., Yu Y.S. TOP2 gene is involved in the pathogenicity of Candida albicans. Mol. Cell. Biochem. 2012;364:45–52. doi: 10.1007/s11010-011-1203-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11010-011-1203-9</ArticleId><ArticleId IdType="pubmed">22203422</ArticleId></ArticleIdList></Reference><Reference><Citation>Reid R.J., Benedetti P., Bjornsti M.A. Yeast as a model organism for studying the actions of DNA topoisomerase-targeted drugs. Biochim. Biophys. Acta. 1998;1400:289–300. doi: 10.1016/S0167-4781(98)00142-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0167-4781(98)00142-0</ArticleId><ArticleId IdType="pubmed">9748633</ArticleId></ArticleIdList></Reference><Reference><Citation>Nitiss J.L., Nitiss K.C. DNA Topoisomerase Protocols. Springer; Berlin, Germany: 2001. Yeast systems for demonstrating the targets of anti-topoisomerase II agents; pp. 315–327.</Citation><ArticleIdList><ArticleId IdType="pubmed">11089243</ArticleId></ArticleIdList></Reference><Reference><Citation>Woo M.H., Vance J.R., Bjornsti M.A. Studying DNATopoisomerase I-Targeted Drugs in the Yeast: Saccharomyces cerevisiae. Methods Mol. Biol. 2001;95:303–313.</Citation><ArticleIdList><ArticleId IdType="pubmed">11089242</ArticleId></ArticleIdList></Reference><Reference><Citation>Webb B., Sali A. Comparative protein structure modeling using Modeller. Curr. Protoc. Protein Sci. 2016;86:5–6. doi: 10.1002/cpps.20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpps.20</ArticleId><ArticleId IdType="pubmed">27801516</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrade-Pavón D., Gómez-García O. Etoposide and Camptothecin Reduce Growth, Viability, the Generation of Petite Mutants, and Recognize the Active Site of DNA Topoisomerase I and II Enzymes in Candida glabrata. Indian J. Microbiol. 2021;61:306–314. doi: 10.1007/s12088-021-00942-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12088-021-00942-6</ArticleId><ArticleId IdType="pmc">PMC8263822</ArticleId><ArticleId IdType="pubmed">34294997</ArticleId></ArticleIdList></Reference><Reference><Citation>Pommier Y., Pourquier P., Fan Y.I., Strumberg D. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim. Biophys. Acta. 1998;1400:83–106. doi: 10.1016/S0167-4781(98)00129-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0167-4781(98)00129-8</ArticleId><ArticleId IdType="pubmed">9748515</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjornsti M.A., Benedetti P., Viglianti G.A., Wang J.C. Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: Restoration of sensitivity of the cells to the antitumor drug camptothecin. Cancer Res. 1989;49:6318–6323.</Citation><ArticleIdList><ArticleId IdType="pubmed">2553253</ArticleId></ArticleIdList></Reference><Reference><Citation>Madden K.R., Champoux J.J. Overexpression of human topoisomerase I in baby hamster kidney cells: Hypersensitivity of clonal isolates to camptothecin. Cancer Res. 1992;52:525–532.</Citation><ArticleIdList><ArticleId IdType="pubmed">1310066</ArticleId></ArticleIdList></Reference><Reference><Citation>Pommier Y. Diversity of DNA topoisomerases I and inhibitors. Biochimie. 1998;80:255–270. doi: 10.1016/S0300-9084(98)80008-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0300-9084(98)80008-4</ArticleId><ArticleId IdType="pubmed">9615865</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta M., Fujimori A., Pommier Y. Eukaryotic DNA topoisomerases i. Biochim. Biophys. Acta. 1995;1262:1–14. doi: 10.1016/0167-4781(95)00029-G.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0167-4781(95)00029-G</ArticleId><ArticleId IdType="pubmed">7772596</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L.F., Desai S.D., LI T.K., Mao Y., Sun M.E.I., SIM S.P. Mechanism of action of camptothecin. Ann. N. Y. Acad. Sci. 2000;922:1–10. doi: 10.1111/j.1749-6632.2000.tb07020.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.2000.tb07020.x</ArticleId><ArticleId IdType="pubmed">11193884</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiang Y.H., Liu L.F. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res. 1988;48:1722–1726.</Citation><ArticleIdList><ArticleId IdType="pubmed">2832051</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Bino G., Lassota P., Darzynkiewicz Z. The S-phase cytotoxicity of camptothecin. Exp. Cell Res. 1991;193:27–35. doi: 10.1016/0014-4827(91)90534-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0014-4827(91)90534-2</ArticleId><ArticleId IdType="pubmed">1995300</ArticleId></ArticleIdList></Reference><Reference><Citation>Kollmannsberger C., Mross K., Jakob A., Kanz L., Bokemeyer C. Topotecan–a novel topoisomerase I inhibitor: Pharmacology and clinical experience. Oncology. 1999;56:1–12. doi: 10.1159/000011923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000011923</ArticleId><ArticleId IdType="pubmed">9885371</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L.F. DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem. 1989;58:351–375. doi: 10.1146/annurev.bi.58.070189.002031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.bi.58.070189.002031</ArticleId><ArticleId IdType="pubmed">2549853</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu W., Huang X.S., Wu J.F., Yang L., Zheng Y.T., Shen Y.M., Li X. Discovery of novel topoisomerase II inhibitors by medicinal chemistry approaches. J. Med. Chem. 2018;61:8947–8980. doi: 10.1021/acs.jmedchem.7b01202.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.7b01202</ArticleId><ArticleId IdType="pubmed">29870668</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortés F., Pastor N. Induction of endoreduplication by topoisomerase II catalytic inhibitors. Mutagenesis. 2003;18:105–112. doi: 10.1093/mutage/18.2.105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/mutage/18.2.105</ArticleId><ArticleId IdType="pubmed">12621064</ArticleId></ArticleIdList></Reference><Reference><Citation>Andoh T., Ishida R. Catalytic inhibitors of DNA topoisomerase II. Biochim. Biophys. Acta. 1998;1400:155–171. doi: 10.1016/S0167-4781(98)00133-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0167-4781(98)00133-X</ArticleId><ArticleId IdType="pubmed">9748552</ArticleId></ArticleIdList></Reference><Reference><Citation>Long B.H. Mechanisms of action of teniposide (VM-26) and comparison with etoposide (VP-16) Semin. Oncol. 1992;19:3–19.</Citation><ArticleIdList><ArticleId IdType="pubmed">1329225</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen L.L., Fostel J.M. DNA topoisomerase inhibitors as antifungal agents. Adv. Pharmacol. 1994;29:227–244.</Citation><ArticleIdList><ArticleId IdType="pubmed">8996610</ArticleId></ArticleIdList></Reference><Reference><Citation>Nitiss J.L., Liu Y.X., Hsiung Y. A temperature sensitive topoisomerase II allele confers temperature dependent drug resistance on amsacrine and etoposide: A genetic system for determining the targets of topoisomerase II inhibitors. Cancer Res. 1993;53:89–93.</Citation><ArticleIdList><ArticleId IdType="pubmed">8380128</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishida R., Hamatake M., Wasserman R.A., Nitiss J.L., Wang J.C., Andoh T. DNA topoisomerase II is the molecular target of bisdioxopiperazine derivatives ICRF-159 and ICRF-193 in Saccharomyces cerevisiae. Cancer Res. 1995;55:2299–2303.</Citation><ArticleIdList><ArticleId IdType="pubmed">7757979</ArticleId></ArticleIdList></Reference><Reference><Citation>Anizon F., Belin L., Moreau P., Sancelme M., Voldoire A., Prudhomme M., Meyer T. Syntheses and biological activities (topoisomerase inhibition and antitumor and antimicrobial properties) of rebeccamycin analogues bearing modified sugar moieties and substituted on the imide nitrogen with a methyl group. J. Med. Chem. 1997;40:3456–3465. doi: 10.1021/jm9702084.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm9702084</ArticleId><ArticleId IdType="pubmed">9341921</ArticleId></ArticleIdList></Reference><Reference><Citation>Hufford C.D., Liu S., Clark A.M., Oguntimein B.O. Anticandidal activity of eupolauridine and onychine, alkaloids from Cleistopholis patens. J. Nat. Prod. 1987;50:961–964. doi: 10.1021/np50053a037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/np50053a037</ArticleId><ArticleId IdType="pubmed">3325614</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan S.I., Nimrod A.C., Mehrpooya M., Nitiss J.L., Walker L.A., Clark A.M. Antifungal activity of eupolauridine and its action on DNA topoisomerases. Antimicrob. Agents Chemother. 2002;46:1785–1792. doi: 10.1128/AAC.46.6.1785-1792.2002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.46.6.1785-1792.2002</ArticleId><ArticleId IdType="pmc">PMC127229</ArticleId><ArticleId IdType="pubmed">12019091</ArticleId></ArticleIdList></Reference><Reference><Citation>Taghavi-Moghadam S., Kwong C.D., Secrist III J.A., Khan S.I., Clark A.M. The synthesis and biological evaluation of alkyl and benzyl naphthyridinium analogs of eupolauridine as potential antimicrobial and cytotoxic agents. Bioorg. Med. Chem. 2016;24:6119–6130. doi: 10.1016/j.bmc.2016.02.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmc.2016.02.028</ArticleId><ArticleId IdType="pubmed">27769668</ArticleId></ArticleIdList></Reference><Reference><Citation>Jannatipour M., Liu Y.X., Nitiss J.L. The top2-5 mutant of yeast topoisomerase II encodes an enzyme resistant to etoposide and amsacrine. J. Biol. Chem. 1993;268:18586–18592. doi: 10.1016/S0021-9258(17)46668-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9258(17)46668-3</ArticleId><ArticleId IdType="pubmed">8395511</ArticleId></ArticleIdList></Reference><Reference><Citation>Knab A.M., Fertala J., Bjornsti M.A. Mechanisms of camptothecin resistance in yeast DNA topoisomerase I mutants. J. Biol. Chem. 1993;268:22322–22330. doi: 10.1016/S0021-9258(18)41531-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9258(18)41531-1</ArticleId><ArticleId IdType="pubmed">8226741</ArticleId></ArticleIdList></Reference><Reference><Citation>Knab A.M., Fertala J., Bjornsti M.A. A Camptothecin-resistant DNA Topoisomerase I Mutant Exhibits Altered Sensitivities to Other DNA Topoisomerase Poisons. J. Biol. Chem. 1995;270:6141–6148. doi: 10.1074/jbc.270.11.6141.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.270.11.6141</ArticleId><ArticleId IdType="pubmed">7890748</ArticleId></ArticleIdList></Reference><Reference><Citation>Reid R.J., Kauh E.A., Bjornsti M.A. Camptothecin sensitivity is mediated by the pleiotropic drug resistance network in yeast. J. Biol. Chem. 1997;272:12091–12099. doi: 10.1074/jbc.272.18.12091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.272.18.12091</ArticleId><ArticleId IdType="pubmed">9115278</ArticleId></ArticleIdList></Reference><Reference><Citation>Keller B.A., Patel S., Fisher L.M. Molecular cloning and expression of the Candida albicans TOP2 gene allows study of fungal DNA topoisomerase II inhibitors in yeast. Biochem. J. 1997;324:329–339. doi: 10.1042/bj3240329.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/bj3240329</ArticleId><ArticleId IdType="pmc">PMC1218434</ArticleId><ArticleId IdType="pubmed">9164874</ArticleId></ArticleIdList></Reference><Reference><Citation>Fostel J., Montgomery D. Identification of the aminocatechol A-3253 as an in vitro poison of DNA topoisomerase I from Candida albicans. Antimicrob. Agents Chemother. 1995;39:586–592. doi: 10.1128/AAC.39.3.586.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.39.3.586</ArticleId><ArticleId IdType="pmc">PMC162588</ArticleId><ArticleId IdType="pubmed">7793856</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwok S.C., Schelenz S., Wang X., Steverding D. In vitro effect of DNA topoisomerase inhibitors on Candida albicans. Med. Mycol. 2010;48:155–160. doi: 10.3109/13693780903114934.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/13693780903114934</ArticleId><ArticleId IdType="pubmed">19626543</ArticleId></ArticleIdList></Reference><Reference><Citation>Steverding D., Evans P., Msika L., Riley B., Wallington J., Schelenz S. In vitro antifungal activity of DNA topoisomerase inhibitors. Med. Micol. 2012;50:333–336. doi: 10.3109/13693786.2011.609186.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/13693786.2011.609186</ArticleId><ArticleId IdType="pubmed">21939347</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan Y., Weinstein J.N., Kohn K.W., Shi L.M., Pommier Y. Molecular modeling studies of the DNA− topoisomerase I ternary cleavable complex with camptothecin. J. Med. Chem. 1998;41:2216–2226. doi: 10.1021/jm9605445.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm9605445</ArticleId><ArticleId IdType="pubmed">9632354</ArticleId></ArticleIdList></Reference><Reference><Citation>Staker B.L., Feese M.D., Cushman M., Pommier Y., Zembower D., Stewart L., Burgin A.B. Structures of three classes of anticancer agents bound to the human topoisomerase I− DNA covalent complex. J. Med. Chem. 2005;48:2336–2345. doi: 10.1021/jm049146p.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm049146p</ArticleId><ArticleId IdType="pubmed">15801827</ArticleId></ArticleIdList></Reference><Reference><Citation>Basili S., Moro S. Novel camptothecin derivatives as topoisomerase I inhibitors. Expert Opin. Ther. Pat. 2009;19:555–574. doi: 10.1517/13543770902773437.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/13543770902773437</ArticleId><ArticleId IdType="pubmed">19441934</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C.C., Li Y.C., Wang Y.R., Li T.K., Chan N.L. On the structural basis and design guidelines for type II topoisomerase-targeting anticancer drugs. Nucleic Acids Res. 2013;41:10630–10640. doi: 10.1093/nar/gkt828.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkt828</ArticleId><ArticleId IdType="pmc">PMC3905874</ArticleId><ArticleId IdType="pubmed">24038465</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar A., Bora U. Molecular docking studies of curcumin natural derivatives with DNA topoisomerase I and II-DNA complexes. Interdiscip. Sci. 2014;6:285–291. doi: 10.1007/s12539-012-0048-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12539-012-0048-6</ArticleId><ArticleId IdType="pubmed">25118649</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan H., Wang G., Li J., Meng G., Liu Z., Dong M., Zhang Q. Synthesis of novel 10-hydroxycamptothecin derivatives utilizing topotecan hydrochloride as ortho-quinonemethide precursor. Bioorg. Med. Chem. 2015;23:118–125. doi: 10.1016/j.bmc.2014.11.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmc.2014.11.020</ArticleId><ArticleId IdType="pubmed">25481395</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris G.M., Huey R., Lindstrom W., Sanner M.F., Belew R.K., Goodsell D.S., Olson A.J. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J. Comput. Chem. 2009;30:2785–2791. doi: 10.1002/jcc.21256.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcc.21256</ArticleId><ArticleId IdType="pmc">PMC2760638</ArticleId><ArticleId IdType="pubmed">19399780</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocha-Del Castillo E., Gómez-García O., Andrade-Pavón D., Villa-Tanaca L., Ramírez-Apan T., Nieto-Camacho A., Gómez E. Dibutyltin (IV) complexes derived from L-DOPA: Synthesis, molecular docking, cytotoxic and antifungal activity. Chem. Pharm. Bull. 2018;66:1104–1113. doi: 10.1248/cpb.c18-00441.</Citation><ArticleIdList><ArticleId IdType="doi">10.1248/cpb.c18-00441</ArticleId><ArticleId IdType="pubmed">30504627</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrade D., Gómez O., Álvarez-Toledano C. Exploring the binding mode of triflamide derivatives at the active site of Topo I and Topo II enzymes: In silico analysis and precise molecular docking. J. Chem. Sci. 2020;132:50.</Citation></Reference><Reference><Citation>Singh S., Das T., Awasthi M., Pandey V.P., Pandey B., Dwivedi U.N. DNA topoisomerase-directed anticancerous alkaloids: ADMET-based screening, molecular docking, and dynamics simulation. Biotechnol. Appl. Biochem. 2016;63:125–137. doi: 10.1002/bab.1346.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bab.1346</ArticleId><ArticleId IdType="pubmed">25594242</ArticleId></ArticleIdList></Reference><Reference><Citation>Song Z.L., Wang M.J., Li L., Wu D., Wang Y.H., Yan L.T., Lee K.H. Design, synthesis, cytotoxic activity and molecular docking studies of new 20 (S)-sulfonylamidine camptothecin derivatives. Eur. J. Med. Chem. 2016;115:109–120. doi: 10.1016/j.ejmech.2016.02.070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2016.02.070</ArticleId><ArticleId IdType="pmc">PMC4834258</ArticleId><ArticleId IdType="pubmed">26994847</ArticleId></ArticleIdList></Reference><Reference><Citation>Drwal M.N., Agama K., Wakelin L.P., Pommier Y., Griffith R. Exploring DNA topoisomerase I ligand space in search of novel anticancer agents. PLoS ONE. 2011;6:e25150. doi: 10.1371/journal.pone.0025150.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0025150</ArticleId><ArticleId IdType="pmc">PMC3178613</ArticleId><ArticleId IdType="pubmed">21966440</ArticleId></ArticleIdList></Reference><Reference><Citation>Laco G.S., Collins J.R., Luke B.T., Kroth H., Sayer J.M., Jerina D.M., Pommier Y. Human topoisomerase I inhibition: Docking camptothecin and derivatives into a structure-based active site model. Biochemistry. 2002;41:1428–1435. doi: 10.1021/bi011774a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi011774a</ArticleId><ArticleId IdType="pubmed">11814334</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Zoghbi M.S., El-Sebaey S.A., Al-Ghulikah H.A., Sobh E.A. Design, synthesis, docking, and anticancer evaluations of new thiazolo [3, 2-a] pyrimidines as topoisomerase II inhibitors. J. Enzym. Inhib. Med. Chem. 2023;38:2175209. doi: 10.1080/14756366.2023.2175209.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14756366.2023.2175209</ArticleId><ArticleId IdType="pmc">PMC9930781</ArticleId><ArticleId IdType="pubmed">36776024</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C.C., Li T.K., Farh L., Lin L.Y., Lin T.S., Yu Y.J., Chan N.L. Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide. Science. 2011;333:459–462. doi: 10.1126/science.1204117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1204117</ArticleId><ArticleId IdType="pubmed">21778401</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh S., Pandey V.P., Yadav K., Yadav A., Dwivedi U.N. Natural products as anti-cancerous therapeutic molecules targeted towards topoisomerases. Curr. Protein Pept. Sci. 2020;21:1103–1142. doi: 10.2174/1389203721666200918152511.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1389203721666200918152511</ArticleId><ArticleId IdType="pubmed">32951576</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabriel I. ‘Acridines’ as new horizons in antifungal treatment. Molecules. 2020;25:1480. doi: 10.3390/molecules25071480.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules25071480</ArticleId><ArticleId IdType="pmc">PMC7180854</ArticleId><ArticleId IdType="pubmed">32218216</ArticleId></ArticleIdList></Reference><Reference><Citation>de Oliveira D.B.C., Silva L.B., da Silva B.V., Borges T.C., Marques B.C., dos Santos M.B., Andrade A.A. A new acridone with antifungal properties against Candida spp. and dermatophytes, and antibiofilm activity against C. albicans. J. Appl. Microbiol. 2019;127:1362–1372. doi: 10.1111/jam.14381.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jam.14381</ArticleId><ArticleId IdType="pubmed">31297951</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>